Long-term Financial ProjectionsHalozyme provides detailed five-year financial guidance, indicating significant growth in total revenues with expectations to achieve $1,565-1,690M by 2028.
Strategic PartnershipsExpectation of more partnerships that could drive upside to current projections for Halozyme, reinforcing confidence in the value potential of the Enhanze platform.
Technology Adoption And Market ShareThe Enhanze platform's ability to convert intravenous drugs to subcutaneous administration could capture a substantial market share in the $41.7B annual U.S. infusion therapy market.